Highlights of This Issue 2721

SPECIAL FEATURES

CCR Translations 2723

Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Michael Pollak
See article p. 2905

Molecular Pathways 2726

Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.B. Seftor, and Mary J.C. Hendrix

CCR Focus 2734

Progress in Pediatric Cancer
Susan E. Bates

Genetically InFormed Therapies—A "GIFT" for Children with Cancer
Carol J. Thiele and Susan L. Cohn

Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthey, Rani E. George, and Alice L. Yu

Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy
Mignon L. Loh and Charles G. Mullighan

Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Elizabeth R. Lawlor and Carol J. Thiele

The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp

Using Germline Genomics to Individualize Pediatric Cancer Treatments
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

Perspective 2801

Disrupting the Networks of Cancer
Daniel F. Camacho and Kenneth J. Pienta

Review 2809

Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?
Peter H. O'Donnell and Walter M. Stadler

HUMAN CANCER BIOLOGY 2817

Suppression of Skeletal Muscle Turnover in Cancer Cachexia: Evidence from the Transcriptome in Sequential Human Muscle Biopsies

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

Clinical Cancer Research
The Journal of Clinical and Translational Research

May 15, 2012 • Volume 18 • Number 10

American Association for Cancer Research
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients</td>
<td>2838</td>
</tr>
<tr>
<td>Daniela Speisky, Aurélie Duces, Ivan Béche, Vinciane Rebour, Pascal Hammel, Alain Sauvanet, Stéphane Richard, Pierre Bedossa, Michel Vidaud, Arnaud Murat, Patricia Niccoli, Jean-Yves Scoaze, Philippe Ruszniewski, and Anne Couvelard for the GTE Group (Groupe d’Étude des Tumeurs Endocrines)</td>
<td></td>
</tr>
<tr>
<td>CANCER THERAPY: CLINICAL</td>
<td></td>
</tr>
<tr>
<td>Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer</td>
<td>2905</td>
</tr>
<tr>
<td>Navid Sadeghi, James L. Abbuzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li</td>
<td></td>
</tr>
<tr>
<td>See commentary p. 2723</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron</td>
<td>2913</td>
</tr>
<tr>
<td>Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O’Mahony, Peter Donachie, and Julian Howell</td>
<td></td>
</tr>
<tr>
<td>Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience</td>
<td></td>
</tr>
<tr>
<td>Jennifer Wheeler, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Betzky Stephen, Sijin Wen, and Razelle Kurzrock</td>
<td></td>
</tr>
<tr>
<td>Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy</td>
<td></td>
</tr>
<tr>
<td>Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432</td>
<td></td>
</tr>
</tbody>
</table>

The Journal of Clinical and Translational Research v www.aacrjournals.org
Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer
Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudio Coco, Giovanni Scambia, Shohreh Shahabi, and Cristiano Ferlini

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Florence de Fraipont, Guénaëlle Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer
Shouyu Wang, Xuming Wu, Yansu Chen, Jianbing Zhang, Jingjing Ding, Yan Zhou, Song He, Yongfei Tan, Fulin Qiang, Jin Bai, Jinyan Zeng, Zhenghua Gong, Aiping Li, Gang Li, Oluf Dimitri Røe, and Jianwei Zhou

Methylation of the tumor suppressor gene Ras association domain family 1A (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluo red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.